Shares of Ambu A/S (OTCMKTS:AMBBY) have received an average rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company.
Several brokerages recently weighed in on AMBBY. Berenberg Bank restated a “buy” rating on shares of Ambu A/S in a report on Tuesday, May 25th. JPMorgan Chase & Co. lowered Ambu A/S from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 18th. Nordea Equity Research lowered shares of Ambu A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 18th. Finally, Danske raised shares of Ambu A/S from a “hold” rating to a “buy” rating in a research note on Monday, July 5th.
Shares of OTCMKTS:AMBBY opened at $34.40 on Friday. Ambu A/S has a twelve month low of $25.55 and a twelve month high of $58.40. The business has a fifty day moving average of $34.56 and a 200-day moving average of $40.75.
Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope.
Recommended Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.